The Pan-Cancer Analysis Uncovers the Prognostic and Immunotherapeutic Significance of CD19 As an Immune Marker in Tumor

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2024 Jun 10

PMID 38855424

Authors

Lanyi Wei

Jingjing Meng

Danfeng Xiang

Quanjun Yang

Yangyun Zhou

Lingyan Xu

Junjun Chen

Yonglong Han

Affiliations

Soon will be listed here.

Abstract

Background: The specific cytotoxic effects of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy have led to impressive outcomes in individuals previously treated for B-cell malignancies. However, the specific biological role of CD19(+) target cells, which exert antitumor immunity against some solid tumors, remains to be elucidated.

Methods: We collected information regarding the level of CD19 mRNA and protein expression from various databases including The Cancer Genome Atlas (TCGA), Tumor Immune Estimation Resource (TIMER), Genotype-Tissue Expression (GTEx), and Human Protein Atlas (HPA) for both tumor and normal samples. To evaluate the patient's prognosis according to CD19 expression, a Kaplan-Meier (KM) analysis and univariate Cox regression were performed. Furthermore, using the Estimation of Stromal and Immune Cells in Malignant Tumor Tissues Using the Expression Data (ESTIMATE) algorithm, we estimated the ratio of immune cells infiltrating malignant tumor tissues. Afterward, the GSCALite repository was employed to evaluate the vulnerability of tumors expressing CD19 to drugs used in chemotherapy. To validate the results in clinical samples of certain cancer types, immunohistochemistry was then performed.

Results: Most tumor types exhibited CD19 expression differently, apart from colon adenocarcinoma (COAD). The early diagnostic value of CD19 has been demonstrated in 9 different tumor types, and the overexpression of CD19 has the potential to extend the survival duration of patients. Multiple tumors showed a positive correlation between CD19 expression and tumor mutation burden (TMB), microsatellite instability (MSI), and ESTIMATE score. Furthermore, a direct association was discovered between the expression of CD19 and the infiltration of immune cells, particularly in cases of breast invasive carcinoma (BRCA). Moreover, CD19 is highly sensitive to a variety of chemotherapy drugs.

Conclusion: The study reveals the potential of CD19 as both a predictive biomarker and a target for different cancer immunotherapies.

References

de Ramon Ortiz C, Wang S, Stathis A, Bertoni F, Zenz T, Novak U . How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?. Hematol Oncol. 2023; 42(1):e3237. DOI: 10.1002/hon.3237. View

Jang J, Thuy P, Lee J, Moon E . CXCR4 promotes B cell viability by the cooperation of nuclear factor (erythroid-derived 2)-like 2 and hypoxia-inducible factor-1α under hypoxic conditions. Cell Death Dis. 2021; 12(4):330. PMC: 7998033. DOI: 10.1038/s41419-021-03615-w. View

Wang J, Li J, Tang G, Tian Y, Su S, Li Y . Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma. Oncol Lett. 2021; 21(4):279. PMC: 7905537. DOI: 10.3892/ol.2021.12540. View

Mihara K, Yoshida T, Takei Y, Sasaki N, Takihara Y, Kuroda J . T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells. J Hematol Oncol. 2017; 10(1):116. PMC: 5465447. DOI: 10.1186/s13045-017-0488-x. View

Schneider D, Xiong Y, Wu D, Hu P, Alabanza L, Steimle B . Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci Transl Med. 2021; 13(586). DOI: 10.1126/scitranslmed.abc6401. View

Kumar S, Singh S, Rana B, Rana A . Tumor-infiltrating CD8 T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today. 2021; 26(4):951-967. PMC: 8131230. DOI: 10.1016/j.drudis.2021.01.002. View

Marin-Acevedo J, Kimbrough E, Lou Y . Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021; 14(1):45. PMC: 7977302. DOI: 10.1186/s13045-021-01056-8. View

Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young L . Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol. 1995; 147(4):1152-60. PMC: 1871000. View

Liu D . CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J Hematol Oncol. 2019; 12(1):113. PMC: 6842223. DOI: 10.1186/s13045-019-0819-1. View

10.

Li B, Severson E, Pignon J, Zhao H, Li T, Novak J . Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016; 17(1):174. PMC: 4993001. DOI: 10.1186/s13059-016-1028-7. View

11.

Pousette J, Johansson A, Jonsson C, Fornander T, Lindstrom L, Olsson H . Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients. Cancers (Basel). 2022; 14(19). PMC: 9564297. DOI: 10.3390/cancers14194844. View

12.

Liu K, Cui J, Zhan Y, Ouyang Q, Lu Q, Yang D . Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. Mol Cancer. 2022; 21(1):98. PMC: 8996591. DOI: 10.1186/s12943-022-01561-5. View

13.

Cheadle E, Gilham D, Thistlethwaite F, Radford J, Hawkins R . Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol. 2005; 129(3):322-32. DOI: 10.1111/j.1365-2141.2005.05456.x. View

14.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

15.

Li B, Yang L . Creatine in T Cell Antitumor Immunity and Cancer Immunotherapy. Nutrients. 2021; 13(5). PMC: 8152274. DOI: 10.3390/nu13051633. View

16.

Jiang Q, Fu Q, Chang Y, Liu Z, Zhang J, Xu L . CD19 tumor-infiltrating B-cells prime CD4 T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. Cancer Immunol Immunother. 2018; 68(1):45-56. PMC: 11028136. DOI: 10.1007/s00262-018-2250-9. View

17.

Susa K, Rawson S, Kruse A, Blacklow S . Cryo-EM structure of the B cell co-receptor CD19 bound to the tetraspanin CD81. Science. 2021; 371(6526):300-305. PMC: 8111558. DOI: 10.1126/science.abd9836. View

18.

Gorgun G, Whitehill G, Anderson J, Hideshima T, Maguire C, Laubach J . Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013; 121(15):2975-87. PMC: 3624943. DOI: 10.1182/blood-2012-08-448548. View

19.

Schiller C, Braciak T, Fenn N, Seidel U, Roskopf C, Wildenhain S . CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells. Oncotarget. 2016; 7(50):83392-83408. PMC: 5347777. DOI: 10.18632/oncotarget.13110. View

20.

Xiang X, He Q, Ou Y, Wang W, Wu Y . Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials. Front Pharmacol. 2020; 11:544754. PMC: 7744881. DOI: 10.3389/fphar.2020.544754. View